Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.02.2014 | editorial

Cure and care for children and adolescents with acute myeloid leukemia in Middle and Eastern European countries: part II

verfasst von: Assoc. Prof. Michael N. Dworzak, MD, PhD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Excerpt

Acute myeloid leukemia (AML), has always been among the most dreadful cancers of childhood and adolescence. Curing this type of leukemia still engages the most intense chemotherapy available in pediatrics, which also contains stem cell transplantation (SCT) in a considerable proportion of cases. …
Vorheriger Artikel The importance of HPV vaccination today
Nächster Artikel Lung cancer screening with low-dose computed tomography
Literatur
1.
Creutzig U, Tallen G. Treatment results for children and adolescents with acute myeloid leukemia in middle and eastern European countries. Memo. 2013;6:5–8.CrossRef
2.
Sramkova L, Sterba J, Hrstkova H, et al. Development of treatment and clinical results in childhood acute myeloid leukemia in the Czech Republic. Memo. 2013;6:41–5.CrossRef
3.
Kolenova A, Bubanska E, Oravkinova I, et al. Development of treatment and clinical results in childhood acute myeloid leukemia in the Slovak Republic. Memo. 2013;6:46–53.CrossRef
4.
Balwierz W, Pawinska-Wasikowska K, Klekawka T, et al. Development of treatment and clinical results in childhood acute myeloid leukemia in Poland. Memo. 2013;6:54–62.PubMedCentralPubMedCrossRef
5.
Krstovski N, Kuzmanovic M, Vujic D, et al. Treatment results of childhood acute myeloid leukemia in Serbia. Memo. 2013;6:63–8.CrossRef
6.
Szegedi I, Jakab Z, Masath P, et al. Development of treatment and clinical results in childhood acute myeloid leukemia in Hungary. Memo. 2013;6:69–72.CrossRef
7.
Boztug H, Mühlegger N, Glogova E, et al. Development of treatment and clinical results in childhood AML in Austria (1993–2013). Memo. 2014;7(1). doi:10.1007/ s12254-014-0135-y.
8.
Polychronopoulou S, Baka M, Servitzoglou M, et al. Treatment and clinical results in childhood AML in Greece. Memo. 2014;7(1). doi:10.1007/s12254-013-0112-x.
9.
Velikonja O, Stefanović M, Kitanovski L, et al. Development of treatment and clinical results in childhood acute myeloid leukemia in Slovenia in the period from 1991 to 2010. Memo. 2014;7(1). doi:10.1007/s12254-013-0090-z.
10.
Creutzig U, Zimmermann M, Dworzak MN, et al. Development of a curative treatment within the AML-BFM studies. Klin Padiatr 2013;225 (Suppl. 1):79–86.
11.
Tallen G, Dworzak M, Gadner H, et al. Imperative of continual support by the European community for future advances in paediatric oncology in Europe: meeting report of the EC-funded sciencecommunication project DIRECT “Overcoming Cancer with Research”. Memo. 2009;2:234–45.CrossRef
12.
Tu JV, Willison DJ, Silver FL, et al. Impracticability of informed consent in the registry of the Canadian stroke network. N Engl J Med. 2004;350:1414–21.PubMedCrossRef
13.
Lauer MS, D’Agostino RB. The Randomized registry trial—the next disruptive technology in clinical research? N Engl J Med. 2013;369:1979–81.CrossRef
14.
Reith C, Landray M, Devereaux PJ, et al. Randomized clinical trials—removing unnecessary obstacles. N Engl J Med. 2013;369:1061–65.PubMedCrossRef
15.
Creutzig U, Ritter J, Zimmermann M, et al. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of study acute myeloid leukemia-Berlin-Frankfurt-Munster 93. J Clin Oncol. 2001;19(10):2705–13.PubMed
16.
Creutzig U, Ritter J, Zimmermann M, et al. Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group. Leukemia. 2001;15(3):348–54.PubMedCrossRef
17.
Creutzig U, Zimmermann M, Bourquin JP, et al. Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16). Blood. 2011;118(20):5409–15.PubMedCrossRef
18.
Creutzig U, Zimmermann M, Bourquin JP, et al. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from study AML-BFM 2004. Blood. 2013;122(1):37–43.PubMedCrossRef
19.
Kaspers GJ, Zimmermann M, Reinhardt D, et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. J Clin Oncol. 2013;31(5):599–607.PubMedCrossRef
Metadaten
Titel
Cure and care for children and adolescents with acute myeloid leukemia in Middle and Eastern European countries: part II
verfasst von
Assoc. Prof. Michael N. Dworzak, MD, PhD
Publikationsdatum
01.02.2014
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2014
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-014-0134-z

Weitere Artikel der Ausgabe 1/2014

Wild-type GIST: a comprehensive review

  • short review

Surgical controversies in esophageal cancer

  • short review

Multi-gene signatures in breast cancer: actual clinical impact

  • short review

Case report of nab-paclitaxel in metastatic pancreatic cancer

  • case report

Untreated endometrial cancer: a case report and a review of the literature

  • short review

Treatment and clinical results in childhood AML in Greece

  • short review